Learning Objectives

Upon completion of the activity, participants should be able to:

Assess recent research and clinical trials of dietary patterns, lifestyle interventions, bariatric/metabolic surgery and weight management medications
Develop an integrative individualized approach to help our patients with metabolic disease
Summarize the safety and efficacy of intermittent fasting diets, including time-restricted feeding, in the management of T2DM
Identify the magnitude and importance of weight bias in healthcare settings and several strategies for mitigating weight bias in clinical practice.
Review the impact of endoscopic manipulation of the gastrointestinal tract on appetite and estimate expected weight loss outcomes of currently available drugs and those on the horizon
Describe noninvasive tests used for identification of patients with NAFLD, NASH and identify those who are at high risk for clinically significant liver fibrosis

Accreditation

Target Audience

This educational initiative is intended for Endocrinologists/members of the Primary Care Team.

Accreditation Statement

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

First	MI	Last	Credentials	Position	Institution	Role	Disclosure(s)
Scott		Kahan	MD, MPH, FTOS	MALE	NCWW/JHU	Speaker	Nothing to disclose
Martin	M	Grajower	MD, FACP, FACE	Clinical Professor of Medicine	Albert Einstein College of Medicine	Speaker	Abbott/AbbVie (Self: 1 financial relationship declared - Honorarium) Bayer (Self: 1 financial relationship declared - Honorarium) echosense (Self: 1 financial relationship declared - Honorarium) Novo Nordisk (Self: 1 financial relationship declared - Honorarium)
Amy		Fischl	MS RDN LDN BC-ADM CDCES		University of Chicago	Speaker	Abbott Diabetes Care (Self: 1 financial relationship declared - Honorarium) Xeris Pharmaceuticals (Self: 1 financial relationship declared - Honorarium)
Monika		Agarwal	MD, MEHP, FACE	Associate Professor	University of Alabama at Birmingham	Speaker	Nothing to disclose
Reshmi		Srinath	MD	Assistant Professor/Director Weight and Metabolism Management Program	Icahn School of Medicine at Mount Sinai	Speaker	Nothing to disclose
Barham		Abu Dayyeh	MD MPH	Director of Advanced Endoscopy and Vice Chair of Innovation	Mayo Clinic, Rochester, MN	Speaker	Apollo Endo-surgery (Self: 1 financial relationship declared - Grant/Research Support) Boston Scientific (Self: 1 financial relationship declared - Grant/Research Support) Endogenex (Self: 1 financial relationship declared - Ownership Interest includes stock, stock options, patent or other intellectual property) Spatz Medical (Self: 1 financial relationship declared - Grant/Research Support) USGI Medical (Self: 1 financial relationship declared - Grant/Research Support)
Taraneh		Solymani	MD	Associate Professor	Penn State College of Medicine	Speaker	Nothing to disclose
Teresa		LaMasters	MD	Medical Director Bariatric Surgery	UnityPoint Clinic Weight Loss Specialists	Speaker	ASMBS (Self: 1 financial relationship declared - Reimbursement for travel and registration as a speaker and board member) Ethicon (Self: 2 financial relationships declared - Honorarium, Consulting Fees (e.g., advisory boards)) INTUITIVE SURGICAL (Self: 2 financial relationships declared - Honorarium, Consulting Fees (e.g., advisory boards)) WL Gore (Self: 2 financial relationships declared - Honorarium, Consulting Fees (e.g., advisory boards))
Holly	F	Lofton	MD, DiplABOM	Clinical Associate Professor of Surgery and Medicine	NYU Grossman School of Medicine	Speaker	Eli Lilly (Self: 1 financial relationship declared - Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received) Novo Nordisk (Self: 3 financial relationships declared - Honorarium, Consulting Fees (e.g., advisory boards), Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)
Zhaoping		Li	MD, PhD		UCLA	Speaker	Nothing to disclose

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.

Summary


Availability:	On-Demand
	Expires on Jul 21, 2023


Cost:	Member: $172.50 Non-Member: $287.50

Credit Offered:

5.75 CME Credits

5.75 ABIM-MOC Points